Heights Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Heights Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Buy	+392,545	New	+$2.28M	0.36%	70

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

FOR

Family Office Research Bethesda, Maryland $230M AUM 23.5% 1-Year Est. Return

Heights Capital Management's IMDX Position: Q1 2026 in Review

Heights Capital Management opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2026: 392,545 shares worth $1.29M. The stake represents 0.36% of the portfolio and ranks #70 among its holdings.

41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

Heights Capital Management held 392,545 shares of Insight Molecular Diagnostics worth $1.29M as of Q1 2026.
Insight Molecular Diagnostics was a new Heights Capital Management position in Q1 2026.
Insight Molecular Diagnostics made up 0.36% of Heights Capital Management's portfolio in Q1 2026, its #70 holding.
41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.